Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 2016

Filing Date
Filed February 28, 2017
Period End
December 31, 2016
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Restructuring8-K · Apr ’19Apr ’19
  2. Leadership change8-K · Oct ’22Oct ’22
  3. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 10-K filed February 28, 2017. Cited figures are marked; the original filing is the authoritative source.

Merck & Co., Inc. reported total sales of $39.8 billiona for the fiscal year ended December 30, 2016, a slight increase of 1% from the prior year, impacted by a 2% unfavorable foreign exchange effect.

The Pharmaceutical segment remains the sole reportable segment, accounting for the vast majority of revenue. Key growth drivers included the oncology franchise, particularly Keytruda, alongside strong performance in Hepatitis C treatments (Zepatier) and vaccines. However, these gains were partially offset by declines in established products like Remicade and Nasonex due to generic and biosimilar competition.

The company made significant investments in research and development, totaling $10.1 billionb, reflecting its commitment to innovation and pipeline expansion. Merck also demonstrated a commitment to shareholder returns, raising its quarterly dividend and repurchasing shares. The company experienced significant IPR&D impairment charges in 2016, notably related to the uprifosbuvir program for HCV, highlighting the inherent risks in drug development.

Legal settlements, including a substantial charge for Keytruda patent litigation, impacted the financial results. Overall, the company navigated a complex operating environment marked by pricing pressures and regulatory scrutiny, while strategically advancing its product portfolio and R&D pipeline.

Key Highlights

  1. Total sales reached $39.8 billion in 2016, a 1% increase year-over-year, with unfavorable foreign exchange impacting results by 2%.
  2. The Pharmaceutical segment is the sole reportable segment, showing growth driven by Keytruda (oncology), Zepatier (HCV), and vaccine products, partially offset by generic competition impacting Remicade and Nasonex.
  3. Research and Development (R&D) expenses significantly increased by 51% to $10.1 billion in 2016, largely due to acquired in-process R&D impairment charges and increased clinical development spending.
  4. The company settled worldwide patent litigation related to Keytruda, recording a pretax charge of $625 million in Q4 2016.
  5. Merck returned $8.6 billion to shareholders in 2016 through dividends and share repurchases, with $5.1 billion in dividends paid.
  6. Significant IPR&D impairment charges of $3.6 billion were recorded in 2016, primarily related to the uprifosbuvir program for HCV and discontinuation of other pipeline programs.
  7. The company divested certain assets and acquired others, including Afferent Pharmaceuticals and IOmet Pharma Ltd., to bolster its pipeline and strategic focus.

Financial Statements

FY2016 against FY2015

Line itemFY2016FY2015Change
Revenue$39.81B$39.50B+0.8%
Cost of Revenue$13.89B$14.93B−7.0%
Gross Profit$25.92B$24.56B+5.5%
R&D Expenses$10.26B$6.70B+53.1%
SG&A Expenses$10.02B$10.31B−2.9%
Interest Expense$693.00M$672.00M+3.1%
Net Income$3.92B$4.44B−11.8%
EPS (Basic)$1.42$1.58−10.1%
EPS (Diluted)$1.41$1.56−9.6%
Shares Outstanding (Basic)2.77B2.82B−1.8%
Shares Outstanding (Diluted)2.79B2.84B−1.9%

Frequently Asked Questions

  1. What were Merck's top-selling products in 2016?

    Merck's top-selling products in 2016 included Januvia/Janumet ($6.1 billion), Zetia/Vytorin ($3.7 billion), Gardasil/Gardasil 9 ($2.17 billion), and Keytruda ($1.4 billion). The pharmaceutical segment accounted for $35.15 billion of total sales.

  2. How did Merck's R&D spending change in 2016, and what were the major drivers?

    Merck's R&D expenses increased significantly by 51% to $10.1 billion in 2016. This surge was primarily driven by acquired in-process R&D impairment charges totaling $3.6 billion (largely for the uprifosbuvir program), increased clinical development spending, and higher restructuring and licensing costs.

  3. What significant legal or settlement events impacted Merck's financial results in 2016?

    Merck recorded a pretax charge of $625 million in the fourth quarter of 2016 related to a settlement and license agreement to resolve worldwide patent infringement litigation for Keytruda. Additionally, the company settled Vioxx shareholder class action litigation, with Merck's net cash payment for the settlement and fees being approximately $680 million.